<DOC>
	<DOCNO>NCT00051051</DOCNO>
	<brief_summary>CI-1033 experimental drug act inhibitor erbB ( EGFR ) receptor , may involve tumor growth . The primary objective study assess antitumor activity CI-1033 patient metastatic breast cancer . Patients histologically confirm metastatic ( Stage IV ) breast cancer receive 2 prior cytotoxic chemotherapy regimens eligible study . CI-1033 administer orally . Patients require blood test periodically receive treatment closely monitor throughout study possible side effect response treatment . Patients may receive prior treatment agent target erbB receptor , include Herceptin ( trastuzumab ) Iressa ( gefitinib ) .</brief_summary>
	<brief_title>A Phase II Study CI-1033 Treating Patients With Metastatic ( Stage IV ) Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Canertinib dihydrochloride</mesh_term>
	<criteria>Female , least 18 year age Histologically confirm diagnosis breast cancer Metastatic ( Stage IV ) disease Progressive recurrent disease follow recent therapy No 2 different , prior cytotoxic chemotherapy regimens metastatic disease At least one measurable target lesion define Response Evaluation Criteria Solid Tumors ( RECIST ) irradiate Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 , determine within 2 week prior randomization Estimated life expectancy &gt; 12 week Capable give write informed consent Capable swallow intact CI1033 capsule Capable understand adhere protocol requirement No prior exposure CI1033 agent target erbB receptor family ( Herceptin , Iressa , Tarceva , IMCC225 , EKB569 ) No know hypersensitivity reaction tyrosine kinase inhibitor Adequate liver , renal , bone marrow function determine within 2 week prior randomization No cytotoxic chemotherapy within 3 week prior baseline disease assessment ( 6 week nitrosoureas mitomycin ) No immunotherapy ( include Herceptin ) biologic therapy within 2 week prior baseline disease assessments No hormone therapy ( include hormone replacement therapy ) within 4 week prior baseline disease assessment ( 6 week megestrol acetate ) Patients must recover acute effect radiation therapy surgery No treatment investigational therapy within 4 week prior baseline disease assessments No history cancer present condition ( except nonmelanoma skin cancer carcinoma situ cervix ) within last 5 year No patient untreated brain metastasis patient recover treatment brain metastases No known malabsorption syndrome condition may impair absorption study medication No comorbidity condition compromise compliance protocol judge investigator would significantly complicate interpretation safety profile CI1033 No patient reproductive potential use method birth control pregnant breastfeed positive pregnancy test baseline Prior exposure CI1033 agent target erbB receptor family ; cytotoxic chemotherapy within 3 week prior baseline disease assessment ( 6 week nitrosoureas mitomycin ) ; immunotherapy ( include Herceptin ) biologic therapy within 2 week prior baseline disease assessment ; hormone therapy ( include hormone replacement therapy ) within 4 week prior baseline disease assessment ; 6 week megestrol acetate ( exclude possibility hormonewithdrawal response ) ; patient untreated brain metastasis .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>